Henry Schein Guides FY Adjusted EPS to $5.42-$5.48, Below $5.54 Consensus
HSIC sits 26% above its 52-week low of $68.7.
Summary
Henry Schein issued full-year guidance calling for adjusted EPS of $5.42-$5.48, short of the $5.54 IBES estimate, with sales growth of 4.5-5.5%. The midpoint lands roughly a dime under consensus, a modest but real shortfall for a company this size. It also sits below the $5.50-$5.56 non-GAAP EPS range the company raised on November 3 alongside Q3 results, so the new outlook walks back the top of that range. The guidance was downgraded to exclude remeasurement gains. The sales growth band is the only other detail disclosed; no margin or segment breakdown accompanied the brief.
At the time of this announcement, HSIC was trading at $86.22 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $9.5B. The 52-week trading range was $68.70 to $92.18. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Reuters.